KZA Media Thread, page-1224

JB- 1), I'm not an authoritarian source. 2) Could do some research but am busy with several projects. (Wonder if Rikki's fence is done), 3) as far as I know, the only restriction to getting voucher approved is if NDA on a particular drug has been approved for any other indication. As an adjuvant, or with an adjuvant, doesn't matter to the FDA. Approval is approval. 4) Thanks for the question., 5) In the possible case of ONC-201 and Paxalisib being effective, they will BOTH be eligible and could monetize their vouchers. Onconeutics (I think) has also received PRDD designation.

Disclaimer: I could be wrong about any or all of that AND I'm not impartial. Think for yourselves. (You could also do some research)